Behold—the Storm Cometh!
Journal of Religion and Violence · 2025 · 10 (2) · 140-168
DOI: 10.5840/jrv2025102/35 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Religion and Violence, 2025. Verfasst von Shelby King.
Abstract (Originalsprache)
To the shock of many of QAnon’s detractors, this millennialist conspiracy movement has not been unmoored by its ties to the violence of the U.S. Capitol riot on January 6, 2021, nor has it crumbled under the weight of numerous failed prophecies. Instead, QAnon has demonstrated a striking resiliency, with some followers more committed to the movement, and still ready to justify violence for the sake of its cause. This essay queries continued commitment in the wake of failed prophecy by examining QAnon alongside the nineteenth-century case of the Millerites, who weathered their “Great Disappointment” in the aftermath of failed predictions of Christ’s Second Coming. By exploring how both movements have invited followers to engage personally in decoding prophecies and unveiling hidden truths, this essay draws attention to the overlooked yet critical role that the experience of revelation plays in mobilizing and sustaining the momentum of millennialist movements when prophecies fail. This essay thus concludes that the experience of revelation is key to the momentum that mobilized QAnon’s followers to take violent actions to hasten the prophesied apocalyptic purge that failed to materialize on January 6th, and re-energized their commitment in the aftermath of their own “Great Disappointment.”
Zitieren
APA
King, S. (2025). Behold—the Storm Cometh!. Journal of Religion and Violence, 10(2), 140-168. https://doi.org/10.5840/jrv2025102/35
Vancouver
King S. Behold—the Storm Cometh!. Journal of Religion and Violence. 2025;10(2):140-168. doi:10.5840/jrv2025102/35
BibTeX
@article{King2025,
author = {King, Shelby},
title = {Behold—the Storm Cometh!},
journal = {Journal of Religion and Violence},
year = {2025},
volume = {10},
number = {2},
pages = {140--168},
doi = {10.5840/jrv2025102/35}
}
EUVIMED